Lymphoma News

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.

The investigational targeted radiotherapy iopofosine I 131 improved survival for certain patients with Waldenström’s macroglobulinemia, according to the agent’s manufacturer.

An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.

Patients with acne who used benzoyl peroxide products did not have a risk for malignancy or increased blood benzene levels, according to a pair of studies published in the Journal of the American Academy of Dermatology.

Women who undergo allogeneic hematopoietic cell transplantation can get pregnant and have healthy children, according to results of a retrospective study conducted in Germany.

New interim results showed that HyBryte treatment demonstrated positive outcomes in patients with early-stage cutaneous T-cell lymphoma, according to a Soligenix press release.

FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.

Certain physical exercises may prevent nerve damage caused by chemotherapy among individuals being treated for cancer, results of a randomized study published in JAMA Internal Medicine showed.

Several hematologists will be honored during this year’s ASH Annual Meeting.

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.